The global Narcolepsy Drug market is projected to expand at a moderate rate during the forecast period. Factors such as increasing awareness about sleep disorders, growing incidence of these disorders due to unhealthy lifestyle, and growth in stress levels are expected to drive the global narcolepsy drug market during the forecast period.
Moreover, large-scale efforts of government and non-governmental organizations for spreading awareness about the disease along with rising R&D activities to find a cure for narcolepsy are the other important factors expected to boost the growth of the narcolepsy drug market in near future. In addition to this, growing health care expenditure and increasing demand for advanced drugs for sleeping disorders are further driving the expansion of this market globally.
On the downside, a lack of awareness among patients and health care providers about the disease in developing countries is likely to hamper the global narcolepsy drug market during the forecast period.
Narcolepsy Drug Market Segment Overview
According to Therapeutics Type, the Sodium Oxybate segment holds the largest share of the market. This is because these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. The sodium oxybate is approved by the FDA to treat cataplexy and excessive daytime sleepiness.
Based on disease type, the Daytime Extreme Sleepiness segment is expected to grow at the highest rate in the coming years. Excessive daytime sleepiness is one of the most common sleep-related symptoms, and it affects an estimated 20% of the population. Also, the rising incidence of narcolepsy and other sleep disorders increases the risk of this symptom, thus it boosting the demand for narcolepsy drugs.
Narcolepsy Drug Market Regional Overview
Region-wise, North America dominated the global Narcolepsy Drug market and is expected to continue its dominance during the forecast period. Factors such as advanced technology, rising awareness among people about the diagnosis of the disease, and high health care expenditure propels the growth of market in North America. similarly, Europe is also expected to account for a significant share of the global market owing to well-established health care infrastructure. Additionally, the Asia Pacific is expected to register the fastest growth during the forecast period. Factors such as development in the health care infrastructure, rising awareness about health, a surge in investment in pharmaceuticals and biotechnology sectors, and high incidence of narcolepsy in countries such as Japan are expected to escalate the growth of the Narcolepsy Drug market in the Asia Pacific region.
Narcolepsy Drug Market Competitor overview
· In June 2021, Jazz Pharmaceuticals plc. announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. Xywav is an oxybate product with a unique composition of cations resulting in 92% less sodium or approximately 1,000 to 1,500 mg/night, than sodium oxybate at the recommended adult dosage range of 6 to 9 grams.
Narcolepsy Drug Market, Key Players
· Ligand Pharmaceuticals
· Addrenex Pharmaceuticals
· Shire Plc
· Teva Pharmaceutical Industries Ltd.
· Arena Pharmaceuticals
· Jazz Pharmaceuticals Plc.
· Bioprojet
· Graymark Healthcare, Inc.
Narcolepsy Drug Market Segmentation
Narcolepsy Drug Market, By Disease Type
· Daytime Extreme Sleepiness
· Cataplexia
· Others
Narcolepsy Drug Market, By Therapeutics Type
· Central Nervous System Stimulants
· Tricyclic Antidepressants
· Sodium Oxybate
· Selective Serotonin Reuptake Inhibitor
· Others
Narcolepsy Drug Market, By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Disease Type
- 5.2.1. Daytime Extreme Sleepiness
- 5.2.2. Cataplexia
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 5.3.1. Central Nervous System Stimulants
- 5.3.2. Tricyclic Antidepressants
- 5.3.3. Sodium Oxybate
- 5.3.4. Selective Serotonin Reuptake Inhibitor
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Latin America
- 5.4.3. Europe
- 5.4.4. Asia Pacific
- 5.4.5. Middle East and Africa
6. North America Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Disease Type
- 6.2.1. Daytime Extreme Sleepiness
- 6.2.2. Cataplexia
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 6.3.1. Central Nervous System Stimulants
- 6.3.2. Tricyclic Antidepressants
- 6.3.3. Sodium Oxybate
- 6.3.4. Selective Serotonin Reuptake Inhibitor
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Latin America Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Disease Type
- 7.2.1. Daytime Extreme Sleepiness
- 7.2.2. Cataplexia
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 7.3.1. Central Nervous System Stimulants
- 7.3.2. Tricyclic Antidepressants
- 7.3.3. Sodium Oxybate
- 7.3.4. Selective Serotonin Reuptake Inhibitor
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. Brazil
- 7.4.2. Mexico
- 7.4.3. Rest of Latin America
8. Europe Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Disease Type
- 8.2.1. Daytime Extreme Sleepiness
- 8.2.2. Cataplexia
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 8.3.1. Central Nervous System Stimulants
- 8.3.2. Tricyclic Antidepressants
- 8.3.3. Sodium Oxybate
- 8.3.4. Selective Serotonin Reuptake Inhibitor
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. UK
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Russia
- 8.4.7. Rest of Europe
9. Asia Pacific Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Disease Type
- 9.2.1. Daytime Extreme Sleepiness
- 9.2.2. Cataplexia
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 9.3.1. Central Nervous System Stimulants
- 9.3.2. Tricyclic Antidepressants
- 9.3.3. Sodium Oxybate
- 9.3.4. Selective Serotonin Reuptake Inhibitor
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. China
- 9.4.2. India
- 9.4.3. Japan
- 9.4.4. Australia
- 9.4.5. South East Asia
- 9.4.6. Rest of Asia Pacific
10. Middle East & Africa Narcolepsy Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Disease Type
- 10.2.1. Daytime Extreme Sleepiness
- 10.2.2. Cataplexia
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast – By Therapeutics Type
- 10.3.1. Central Nervous System Stimulants
- 10.3.2. Tricyclic Antidepressants
- 10.3.3. Sodium Oxybate
- 10.3.4. Selective Serotonin Reuptake Inhibitor
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Country
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Company Market Share Analysis, 2018
- 11.2. Key Industry Developments
- 11.3. Company Profile
- 11.4. Ligand Pharmaceuticals
- 11.4.1. Business Overview
- 11.4.2. Segment 1 & Service Offering
- 11.4.3. Overall Revenue
- 11.4.4. Geographic Presence
- 11.4.5. Recent Development
- 11.5. Addrenex Pharmaceuticals
- 11.6. Shire Plc
- 11.7. Teva Pharmaceutical Industries Ltd.
- 11.8. Arena Pharmaceuticals
- 11.9. Jazz Pharmaceuticals Plc.
- 11.10. Bioprojet
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
